chronic obstructive pulmonary disease (COPD)
Conditions
Interventions
3.2 g/day) or
placebo for 8-10 weeks.
Sponsors
CIRO
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Objective diagnosis of COPD, GOLD group B or D (high symptomatic) - Clinically stable according to the pulmonary physician, i.e. no exacerbation and/or hospitalization within the previous 4 weeks. - Age between 40-80 years - Attending the regular inpatient pulmonary rehabilitation program in CIRO - No use of anabolic steroids during the inpatient pulmonary rehabilitation program in CIRO
Exclusion criteria
Exclusion criteria: - Instable cardiac disease - Neurological disease and/or musculoskeletal disease that preclude safe participation in an exercise test - History of drugs/alcohol abuse in the past 10 years - Vegetarianism - Inability to understand the Dutch language - Self-reported β-alanine supplementation in the past 3 months - Participation in pulmonary rehabilitation within the past 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Exercise tolerance, defined as the change in cycle endurance time (before andafter the rehabilitation period), measured during a constant work rate cycletest (CWRT) | — |
Secondary
| Measure | Time frame |
|---|---|
| Lower-limb muscle function, 6-minute walking distance, fatigue, disease specific quality of life, body composition, dyspnoea, symptoms of anxiety and depression, physical activity, problematic activities of daily life, mobility, cognitive function, respiratory muscle strength, systemic beta-alanine, carnosine, taurine and histidine, systemic inflammatory and oxidative stress markers, muscle beta-alanine, carnosine, taurine and histidine, muscle inflammation and oxidative stress and inflammatory and oxidative stress markers in the lungs, therapy adherence, patient safety and supplement duration. | — |
Countries
Netherlands
Contacts
Public ContactB. Brauwers
CIRO
Outcome results
None listed